More than 10,000 MCP connectors are already running across finance, legal, and software industries, and clinical trials are only beginning to catch up. That gap matters because the underlying standard, Model Context Protocol, has moved from Anthropic side project to neutral infrastructure faster than most trial technologists have noticed. Anthropic open-sourced it in November 2024, and by December 2025 governance had transferred to the Agentic AI Foundation under the Linux Foundation, removing single-vendor control and accelerating adoption across competing platforms.
The practical shift for sponsors and CROs is this: before MCP, connecting an AI tool to an EDC or CTMS meant commissioning a one-off integration, which could consume weeks of engineering time a small team rarely has. An MCP connector flips that. A vendor builds to the common standard once, and any customer with appropriate permissions can activate it without a separate build. The AI tool then reaches into live systems, pulling real enrollment figures, supply levels, or protocol deviation counts, instead of waiting for someone to paste data into a chat window. A query like “which sites are behind on enrollment and low on supply?” becomes answerable directly from source systems rather than from a manually assembled spreadsheet.
Finance and legal moved faster here, deploying MCP-connected tools for fraud detection and case research in production environments. Clinical trials carry additional regulatory weight, and the FDA’s current posture is a risk-based credibility framework for AI supporting regulatory decisions rather than a prescriptive rulebook. That means trial teams adopting MCP connectors need to configure access controls carefully at setup: deciding which users can query which systems, and what the AI tool is permitted to modify, not just read. Those decisions happen once, but they determine the compliance exposure of everything that runs on top.
Adoption inside clinical trial software is still early. Medidata has released an MCP connector for Claude covering platform documentation queries and predictive site ranking, which gives a concrete picture of what current implementations actually do versus what the technology could eventually do. Sponsors evaluating vendors should ask directly about MCP roadmaps rather than assuming the capability is live. The question worth tracking is how quickly EDC and CTMS vendors extend connector coverage beyond documentation and into writeable workflows, since read-only access is useful but write access is where the meaningful time savings appear.
Source link: https://medrio.com/blog/mcp-connector-clinical-trials/
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
